Braxia Scientific Corp Shows Resilience Amid Financial Challenges

Braxia Scientific Corp., a name that has been under significant scrutiny due to its financial health, recently unveiled its financial results for the quarter ending December 31, 2023. Amidst a challenging financial landscape, the company has shown a glimmer of resilience, reporting a modest increase in revenue by 0.7% to $0.492 million for the quarter….

Silo Wellness

Silo Wellness Announces Extension of Kaya/NUGL LOI; Annual Filings Delay

Springfield, Oregon–(Newsfile Corp. – February 27, 2024) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) (“Silo” or “the Company”), a leading global psychedelics wellness company, announces that the Letter of Intent (LOI) to acquire NUGL (Kaya Group in Jamaica) previously announced on August 29, 2023 has been extended through June 1, 2024. The extension provides…


MindMed Reports 2023 Financial Results and Business Updates

NEW YORK, February 28, 2024–(BUSINESS WIRE)–Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the year ended December 31, 2023 and provided a business update. “2023 was a highly productive year for MindMed,…

Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

MELBOURNE, Australia and NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce positive topline results from its Phase 2 Psi-GAD1 clinical trial of psilocybin in generalised anxiety disorder (GAD). The trial met its primary endpoint, demonstrating a large clinical effect…